About GLP1Score
GLP1Score is India's most comprehensive free GLP-1 eligibility assessment platform. Our mission: make GLP-1 therapy information accessible, affordable, and evidence-based for every Indian. India has 101 million people with diabetes and 254 million with obesity.
How Our Scoring Works
Our 30-question clinical assessment evaluates 6 dimensions: Body Composition (25%), Medical Profile (25%), Safety/Contraindications (20%), Treatment Readiness, Access & Affordability, and Motivation. Built on 20 peer-reviewed clinical studies including the STEP trials, SELECT trial, ICMR-INDIAB, and WHO guidelines. Uses South Asian BMI cutoffs. Red flags for MTC, pregnancy, and Type 1 diabetes trigger hard score caps.
Our Clinical Sources
- ESI India Obesity Guidelines (2023)
- ICMR-INDIAB National Study (2023)
- WHO GLP-1 Guideline (2025)
- ADA Standards of Care (2026)
- WHO Asia-Pacific BMI Guidelines
- FDA Prescribing Information — Ozempic and Wegovy
- DCGI India Regulatory Advisory (2026)
Our Independence
GLP1Score is not affiliated with Novo Nordisk, Eli Lilly, Sun Pharma, Dr. Reddy's, or any pharmaceutical manufacturer. No pharmaceutical sponsorship or advertising. Data sourced from public launch announcements and verified pharmacy pricing.
Contact
Email: hello@glp1score.com | Founded: March 2026
Take the Free Assessment | View Our Evidence Library